ID | 1237 |
Name of the vaccine | VPM1002 |
Microbe | Bacteria |
Disease name | Pulmonary Tuberculosis (TB) |
Name of bacteria | Mycobacterium tuberculosis |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | 18 to 65 years |
Description of the vaccine | Recombinant BCG vaccine from the Mycobacterium bovis BCG subtype Prague. |
Name of the manufacturer | Serum Institute of India Pvt. Ltd. |
Name of the manufacturing country | Bangladesh, India |
Year of manufacture | 2022 |
Clinical Phase status | Clinical - Phase 2, Phase 3 |
Bacterial strain | Acid-fast Gram-positive bacteria. |
Efficacy | NA |
Vaccine formulation | Lyophilized |
Dosage | Single dose. |
Mechanism of action | NA |
Route of administration | Intradermal |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT03152903 |
Reference | NA |
Other name | NA |
Additional Links | NA
|